$54M merger including valuation, negotiations, and closing of the merger including support for FDA Pre Market Approval, clinical trials, and manufacturing scale-up with a new business model and corporate strategy for US and global market entry.
$105M ORAL SURGERY ROLL UP: Sourced, packaged, and represented as sell-side M&A advisors in a multi-state oral surgery practice roll up of 21 offices, 31 doctors in 3 states valued together at $105MM for majority sale with equity and earnouts financed by a PE fund.
$34M DENTAL ROLL UP: Sourced, packaged, and represented as sell-side M&A advisors for a multi-state general dentist practice roll up of 7 doctor owners in 3 states valued together at $34M for the US market entry of a Canadian DSO financed by a Toronto-based family office and a US-based healthcare private equity firm and credit facility.
$32M MERGER AND LEVERAGED BUYOUT: Provided deal sourcing, valuation, synergy, negotiations, and post-transaction integration support in the merger of specialty infectious disease prevention and communications consulting firm as a public health carveout.
$210MM STRATEGIC SALE: Identified and prequalified strategic investors for synergies, including selected strategic buyer, in the successful acquisition of the company while providing post-LOI diligence and revenue forecasting with business development and prototyping guidance for next-gen single-use GI devices and infection control treatments.
$ 4.2M RAISE: Provided capital raise pitch, valuation, branding, prototyping, and market analysis guidance as part of a successful seed raise with well known Foundation and Innovation Center, followed by sourcing VC funding for a handheld, disposable biochemical device startup that provides accurate, quantitative evaluation of anemia in less than two minutes.
$ 7.2M RAISE: Provided capital raise pitch, valuation, market analysis and business development guidance in successful capital raise and 150% revenue growth with new clients via 2 years of foundation seed grants, followed by VC seed investment for this artificial intelligence-driven fraud detection and investigation startup that identifies and mitigates payments of fraudulent healthcare billing for private/government payors.
$ 5.2M+ RAISE and JVs: Provided valuation, business model, marketing, and capital raise consulting for a ceramics, metal and biopolymer 3D printing (3DP) startup that provides custom design software and patented 3DP laser platforms to manufacture or prototype advanced aerospace engine and medical surgical parts/devices. MCS’ efforts secured joint ventures with a leading jet engine manufacturer and a large maintenance, repair and overhaul (MRO) company, as well as successful capital raises totaling $5.2M from a family office and undisclosed multi-million VC Series A investment.
$250K STUDY FOR $205M CARVEOUT: As as buy-side M&A advisors, MCS partners delivered global market revenue, supply chain expense forecasts, and technical scouting of future merger targets with a leading innovation center. This informtaion was used for a Tier 1 global investment bank valuation opinion to be provided to a global PE group in a $205M leveraged buyout of a medical aesthetics company that manufactures laser devices for skin revitalization, body contouring, hair removal, and women’s health sold in over 130 countries.
$34MM REVERSE MERGER RAISE & NEW PRODUCT LAUNCH: We successfully brought several new distilled spirit brands to market including distillation, bottling, distribution, marketing, importation, distribution, and sales. The company successfully entered the public markets, achieving and holding a $30M+ market cap. Their two top spirits (vodka) achieved Gold Standard in World Spirits Competition.
$30MM MERGER CONSOLIDATION: Negotiated and managed the consolidation including all valuation, supply chain contracting, and corporate restructuring. We merged two Taiwanese OEM wheel manufacturers into a Chinese OEM wheel manufacturer headquartered in China resulting in a merged company. Results included combined annual revenue growth of 20% to over $100M USD with a 14% reduction in COGS and funds to open a new manufacturing facility.
$60MM STRATEGIC ACQUISITION: We implemented a corporate restructuring and acquisition/sale strategy to acquire majority ownership of a US and Germany-based lithium ion battery manufacturer through the acquisition of an Hague-based investment company that owned the required warrants, to be exercised post-acquisition for 56.2% ownership. Negotiated the relief of $20MM USD in debt and placed all assets and IP into an SPV, and restructured the company, which was sold to a large battery manufacturer in Bulgaria.
MCS brings C-Suite and Board-level guidance to new heights that clarifies all aspects of your corporate strategy development and execution, ensuring direction and momentum as you grow, evolve or plan an exit.
MCS positions companies for successful M&A with capital introductions and negotiations at all stages for each transaction.
We provide our clients with selective access to our exclusive MCS Investor Network of financing partners from commercial banks and private equity groups to family offices, venture capital groups, angel and high net-worth investors.
If the timing of the M&A transaction is not quite right yet, MCS repositions companies for successful M&A via tried-and-true corporate restructuring and market readiness guidance.
MCS’s executives have decades of marketing strategy and product launch experience in every sector in which we specialize.
Investor relations are at the core of obtaining support and attaining results; such an impact can propel a company’s profitability, growth, and market share, independent of the type of industry or the size of the enterprise.
We provide end-to-end regulatory affairs services that span the entire drug life cycle from early development through to submission and license approval to post-approval marketing maintenance. We support manufacturers, packagers, labelers, suppliers, distributors, importers, and warehouses.
We provide GCP, GLP, and GMP consulting services for pharmaceuticals, natural health products, medical devices, cosmetics, and over-the-counter products.
The importation of regulated products into Canada requires prior approvals. We provide a clear path to product and establishment licenses while developing and maintaining your quality management system. License access includes drug products, OTC, natural health products (NHP), medical devices, active pharmaceutical ingredients (API), and cosmetics.